

Table 3 Preoperative patient characteristics of standard high-risk cohort

	SHR unmatched cohort			Propensity score-matched cohort		
	LN yield $\geq$ 15 (<i>n</i> =108)	LN yield<15 (<i>n</i> =145)	<i>p</i>	LN yield $\geq$ 15 (<i>n</i> =75)	LN yield<15 (<i>n</i> =75)	<i>p</i>
Mean age, years (SD)	66.6 (5.9)	68.4 (5.5)	0.012	67.1 (5.6)	68.0 (5.4)	0.278
Mean BMI, kg/m ² (SD)	24.7 (2.5)	24.5 (2.7)	0.492	24.7 (2.5)	24.6 (2.7)	0.771
Mean PSA, ng/mL (SD)	8.9 (5.3)	9.4 (7.2)	0.524	8.9 (5.3)	9.5 (8.4)	0.615
Mean PV, mL (SD)	38.9 (13.2)	41.5 (17.8)	0.211	39.3 (11.8)	40.4 (15.9)	0.624
Clinical T-stage, <i>n</i> (%)			0.121			0.911
T1c	16 (14.8)	32 (22.1)		14 (18.7)	17 (22.7)	
T2a-c	83 (76.9)	108 (74.5)		57 (76.0)	54 (72.0)	
T3a	9 (8.3)	5 (3.4)		4 (5.3)	4 (5.3)	
Mean biopsy cores (SD)	15.4 (2.5)	17.1 (3.0)	<0.001	15.8 (2.6)	15.6 (2.7)	0.647
Mean positive cores (SD)	4.9 (2.6)	4.0 (2.5)	0.004	4.3 (2.3)	4.5 (2.8)	0.656
ISUP grade group, <i>n</i> (%)			0.627			0.451
1-2	7 (6.5)	5 (3.4)		6 (8.0)	5 (6.7)	
3	6 (5.6)	9 (6.2)		1 (1.3)	5 (6.7)	
4	81 (75.0)	110 (75.9)		57 (76.0)	56 (74.7)	
5	14 (13.0)	21 (14.5)		11 (14.7)	9 (12.0)	
Androgen deprivation, <i>n</i> (%)			0.122			0.780
Received	9 (8.3)	22 (15.2)		8 (10.7)	6 (8.0)	
Not received	99 (91.7)	123 (84.8)		67 (89.3)	69 (92.0)	
Mean Briganti LNI, % (SD)	14.5 (9.6)	11.2 (6.4)	0.001	11.7 (4.5)	12.4 (8.1)	0.544

SHR=standard high-risk (Johns Hopkins University criteria); LN=lymph node; SD=standard deviation; BMI=body mass index; PSA=prostate-specific antigen; PV=prostate volume; ISUP=International Society of Urological Pathology;